KAS
RCUS icon

Kemnay Advisory Services’s Arcus Biosciences RCUS Stock Holding History

Kemnay Advisory Services’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Buy
800
+88
+12% +$2.17K ﹤0.01% 610
2026
Q1 		$15.4K Buy
+712
New +$15.4K ﹤0.01% 833

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Kemnay Advisory Services's RCUS Position: Q2 2026 in Review

Kemnay Advisory Services increased its Arcus Biosciences (RCUS) stake by 12% in Q2 2026, buying an estimated $2.17K and bringing the position to 800 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

Kemnay Advisory Services first reported a position in RCUS in Q1 2026 and has held it in 2 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Kemnay Advisory Services held 800 shares of Arcus Biosciences worth $24.7K as of Q2 2026.
  • Kemnay Advisory Services bought 88 Arcus Biosciences shares in Q2 2026, an estimated $2.17K.
  • Arcus Biosciences made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #610 holding.
  • Kemnay Advisory Services first reported a position in Arcus Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.